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ABSTRACT 
Post-transcriptional control of gene expression is mediated via RNA-binding proteins 
(RBPs) that interact with mRNAs in a combinatorial fashion. While recent global RNA 
interactome capture experiments expanded the repertoire of cellular RBPs quiet 
dramatically, little is known about the assembly of RBPs on particular mRNAs; and 
how these associations change and control the fate of the mRNA in drug-treatment 
conditions. Here we introduce a novel biochemical approach, termed tobramycin-
based tandem RNA isolation procedure (tobTRIP), to quantify proteins associated with 
the 3’UTRs of cyclin-dependent kinase inhibitor 1B (CDKN1B/p27Kip1) mRNAs in vivo. 
P27Kip1 plays an important role in mediating a cell’s response to cisplatin (CP), a widely 
used chemotherapeutic cancer drug that induces DNA damage and cell cycle arrest. 
We found that p27Kip1 mRNA is stabilized upon CP treatment of HEK293 cells through 
elements in its 3’UTR. Applying tobTRIP, we further compared the associated proteins 
in CP and non-treated cells, and identified more than fifty interacting RBPs, many 
functionally related and evoking a coordinated response. Knock-downs of several of 
the identified RBPs in HEK293 cells confirmed their involvement in CP-induced p27 
mRNA regulation; while knock-down of the KH-type splicing regulatory protein 
(KHSRP) further enhanced the sensitivity of MCF7 adenocarcinoma cancer cells to 
CP treatment. Our results highlight the benefit of specific in vivo mRNA-protein 
interactome capture to reveal post-transcriptional regulatory networks implicated in 
cellular drug response and adaptation. 
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Introduction 
Post-transcriptional regulation of gene expression plays a pivotal role in maintaining 
cellular homeostasis. As aberrant control of cellular homeostasis contributes to 
cancer, this may implicate post-transcriptional processes in cancer progression or 
treatment (1,2). Post-transcriptional control is mainly exerted by the interaction of a 
specific target mRNA with one or more RNA-binding proteins (RBPs) or non-coding 
RNAs (ncRNAs) such as microRNAs (miRNAs), which occur preferentially in the 
untranslated regions (UTRs) of cytoplasmic mRNA and in a combinatorial fashion 
(3,4). Importantly, the dynamic assembly of RBPs and/or ncRNAs orchestrates all 
aspects of an mRNA’s life; from RNA processing events in the nucleus (i.e. splicing), 
to the control of mRNA stability, translation or localisation to the cytoplasm. Recently, 
global experimental exploration of RBPs in diverse organisms has become popular, 
with some studies exploring the dynamics of mRNA-RBP association upon changing 
environmental conditions (5-8). However, changes in specific mRNA-RBP interactions 
between conditions are currently understudied. This is likely because the applicability 
of existing experimental approaches is limited. Current approaches involve either the 
affinity purification of mRNAs with specifically designed anti-sense oligonucleotides 
(ASOs) (e.g., (9-11)) or the recovery of tagged mRNAs via specific ligands or proteins 
(12,13).The level of specificity and efficiency of target mRNA capture is a common 
limitation of these approaches, especially for in vivo applications, as well as low mRNA 
copy number. We thus developed a novel two-step tobramycin aptamer-based 
purification strategy, termed tobTRIP, to identify proteins bound to the 3’ untranslated 
regions (UTR) of specific mRNAs. The approach complements our previous tandem 
RNA affinity isolation procedure (TRIP) by using ASOs to capture endogenous mRNAs 
(10,11). 
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Cisplatin (CP; cis-diamminedichloroplatinum(II)) is a widely used 
chemotherapeutic agent for treating human cancers (14-16). CP binds to DNA and 
forms intra- and inter-strand DNA cross-links as well as mono adducts, which mediate 
cytotoxic effects by interfering with transcription and replication and ultimately lead to 
the induction of cell death through apoptosis (14-16). Importantly, several studies 
monitoring the effects of CP on gene expression suggest the involvement of post-
transcriptional regulatory mechanisms, although the specific mediators remain 
unknown (17-19). Cell-cycle control is one of the major checkpoints for DNA repair 
and a key process for tumour progression and maintenance (20,21). Transition from 
G1 to S phase of the cell-cycle is controlled by p27 (also referred to CDKN1B or Kip1), 
a negative regulator of CDK2 and cyclin E expression that prevents entry of cells into 
S phase (22). p27 has been long thought to mainly act as a tumour suppressor since 
it can halt the cell-cycle and promotes apoptosis (23). Conversely, p27 has also been 
shown to have anti-apoptotic effects by protecting cells from cytotoxic stress (24). Most 
relevant to this work is that there is evidence for post-transcriptional control of p27 with 
potential implications in cancer therapy. For example, p27 is induced in non-small cell 
lung cancer (NSCLC) tumours and shown to be post-transcriptionally controlled by the 
RBP hnRNPA0, which promotes DNA repair and makes cells tolerant to chemotherapy 
(24). As such, p27 can drive tumorigenesis (25), with high levels of p27 correlated with 
CP resistance (e.g., (26)). Nevertheless, the reported implications of p27 for tumour 
growth and drug resistance are diverse, possibly reflecting the complexity and 
differences in the cellular composition of different tumour types. 
To further our understanding of RBP-mediated post-transcriptional regulation 
of p27 mRNAs in response to CP drug response, we used tobTRIP to investigate the 
binding of RBPs before and after CP treatment of HEK293 cells, which have been 
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shown to be sensitive to CP (27). We established that p27 mRNA is stabilised upon 
CP treatment, while translation is generally repressed. Applying tobTRIP, we could 
identify a network of RBPs associated with the 3’UTR of p27. Knock-down of selected 
RBPs inhibited induction of p27 mRNA levels upon CP treatment in HEK293 cells, 
while KHSRP knock-down enhanced the sensitivity of MCF7 adenocarcinoma cancer 
cells to CP treatment. Our results therefore highlight the importance of post-
transcriptional regulation in drug response and KHSRP for modulation of drug 
sensitivity. 
 
Results 
Post-transcriptional regulation of p27 in CP-treated HEK293 cells 
To evaluate the inhibition of cell-growth by CP we compared cell proliferation of 
HEK293 and MCF7 cells in the presence (20 µM) and absence of CP. As reported 
(27), we observed a significant reduction in cell proliferation of CP-treated HEK293 
after 24 hours (h) (Figure 1(a)). Contrarily, MCF7 cells, a human breast 
adenocarcinoma cell line considered to be relatively resistant to CP treatment (28), 
were still proliferating after 24 h in the presence of CP with some slight growth 
reduction after 48 h. Furthermore, the fraction of dead cells was significantly higher in 
CP-treated HEK293 cells, whereas no significant differences were observed for MCF7 
cells (Figure 1(b)). These results are in line with increased cytotoxic effects of CP in 
HEK293 compared to MCF7 cells. 
Since expression of p27 has been linked to the DNA damage response, which 
can be triggered by CP, we compared p27 mRNA and protein levels in CP-treated 
versus untreated cells (Figure 1(c), (d); uncropped immunoblots are provided in the 
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Supplemental Material). Thus, we focused on 15 h CP treatment to minimize potential 
secondary effects induced by defects in cellular proliferation that can occur after 
prolonged exposure to CP. p27 mRNA levels were increased after 15 h of CP 
treatment, whereas protein levels were slightly reduced in HEK293 cells; the latter in 
agreement with previous data obtained in other cells (i.e., MHM, U2OS and S4 cells) 
(29). Contrarily, no significant changes in p27 mRNA and protein levels were observed 
in MCF7 cells. CP treatment leads to the activation of members of the tumour protein 
p53 family of transcription factors, which, in turn, alter the expression of downstream 
target genes leading to increased DNA repair, cell-cycle arrest and eventually 
apoptosis (15,30). Furthermore, it has been reported that p53 upregulates p27 
expression in breast cancer (31). As could be expected, p53 mRNA and protein levels 
were significantly elevated in CP-treated HEK293 cells after 15 h as compared to 
untreated cells (Fig 1(c), (d)). Conversely, no substantial increase of p53 protein and 
mRNA levels was observed in MCF7 cells upon CP treatment for 15 h (Fig. 1(c), (d)), 
although extended application of CP for 48 h led to some increase of p53 levels (data 
not shown). Notably, p53 protein levels were increased in MCF7 cells exposed to 2 
µg/ml of ActD for 3 h, a condition known to activate p53 (32) and confirms the integrity 
of the p53 pathway in MCF7 cells (Figure 1(d)). The observed different responses on 
p27 and p53 level in HEK293 as compared to MCF7 upon CP treatment are therefore 
in line with the different sensitivities of cells to CP treatment and the associated 
physiological response, such as DNA damage response.  
We next tested whether CP administration compromises translation, which may 
explain the observed slight reduction in p27 protein levels despite increased mRNA 
levels. An analysis of polysomal profiles obtained from CP-treated and untreated 
HEK293 cells showed an accumulation of 80S monosomes concomitant with a 
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reduction of polysomes, indicative of general inhibition of protein synthesis 
(Supplemental Figure S1(a)). Moreover, p27 mRNAs shifted from heavy polysomes to 
light polysomes upon CP treatment (Supplemental Figure S1(b)). However, similar 
shifts from heavy/lighter polysomes to subpolysomes were seen for tubulin (TUBB) 
and - even more pronounced - for RPS18, a terminal oligopyrimidine track (TOP) 
sequence-bearing mRNA known to be particularly affected in translation upon stress 
conditions (33). We thus concluded that translation is generally inhibited upon CP 
treatment of cells and therefore not specific to p27 mRNA.  
We next wondered whether application of CP induces the formation of stress-
granules (SGs), which could explain the general inhibition of protein synthesis (34). 
However, CP treatment did not lead to the visible formation of SGs after 15 h, 
indicating that CP-mediated inhibition of protein synthesis does not coincide with 
formation of SGs (Supplemental Figure S2). 
 The increased p27 mRNA levels in CP-treated HEK293 cells could be 
explained by reduced mRNA turnover and/or increased production through 
transcription. We therefore investigated whether the stability of p27 mRNA is affected 
in CP-treated compared to untreated cells by addition of ActD as a potent inhibitor of 
transcription (32). Indeed, we found that p27 mRNA became more stable in CP-treated 
cells (P = 0.02, two-tailed student’s t-test), whereas no significant alterations in the 
stability was observed for c-myc mRNA (P = 0.23), a relatively unstable mRNA species 
(35) (Figure 1(e)). These results suggest that p27 mRNA is specifically stabilised upon 
short (15 h) CP treatment, while its translation is slightly inhibited, likely through a 
global decrease in translation efficiency. However, it is important to note that increased 
mRNA stability does not exclude the possibility for increased transcription of p27, 
which could also contribute to the observed increase of p27 mRNA levels in CP treated 
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cells. Moreover, whether the apparent paradox implemented by the observed increase 
of p27 mRNA stability along its translation repression could relate to alternative 
functions of p27 mRNAs, such as regulatory or epigenetic functions would need further 
investigation (36).  
 
P27 gene expression is post-transcriptionally regulated by the 3’UTR of its 
mRNA 
Since mRNA stability is often controlled through RNA-protein interactions in the 
3’UTR, we wanted to test whether the 3’UTR contributes to the stabilisation of p27 
mRNAs in CP-treated HEK293 cells. Therefore, we generated HEK293 cell lines that 
allow tetracycline (tet)-inducible expression of the p27 3’UTR from a stable integrated 
plasmid. The integrated construct contains the coding sequence of green fluorescent 
protein (GFP), as well as the sequence for a novel RNA affinity tag, termed HAMMER2 
(T-apt), located between the GFP coding sequence and the p27 3’UTR (Figure 2(a)). 
The HAMMER2 tag comprises a J6f1 aptamer, which efficiently interacts with 
tobramycin (Kd = 5 nM, (37)), and is flanked by linker sequences in order to stabilise 
the local RNA aptamer structure, as well as restriction sites for DNA sub-cloning of 
alternate aptamers and 3’UTR sequences (construction and features of HAMMER2 
and corresponding plasmids for generation of cell lines are outlined in the 
Supplemental Figure S3). The tet-inducible expression of GFP in stable cell lines 
containing (GFP-T-p27(3’UTR)) or lacking the 3’UTR of p27 (GFP-T) was validated by 
fluorescence microscopy and immunoblot analysis (Supplemental Figure S4). The 
latter revealed that inclusion of the p27 3’UTR leads to reduction in GFP expression, 
indicating inhibitory functions of the 3’UTR for gene expression. 
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To test whether the observed increase in p27 mRNA upon CP treatment can 
be recapitulated by its 3’UTR alone we treated GFP-T-p27(3’UTR) and GFP-T cells 
for 15 h with CP. CP treatment significantly increased the abundance of the GFP-T-
p27(3’UTR) mRNA to levels similar to that of endogenously expressed p27, but not 
those of GFP-T mRNA lacking the p27 3’-UTR (Figure 2(b)). Conversely, GFP protein 
levels remained constant or were slightly decreased in both GFP-T and GFP-T-
p27(3’UTR) cells, in agreement with the previously observed general reduction of 
translation upon CP treatment (Supplemental Figure S4(b)). Finally, we measured the 
relative mRNA stability of the reporter GFP-T-p27(3’UTR) upon CP treatment. As 
previously seen with the endogenous p27 mRNAs, we found substantial stabilisation 
of the reporter mRNAs upon CP treatment (P = 0.037), while c-myc was not changed 
(P = 0.97)(Figure 2(c)). These results strongly suggest that (i) sequences in the 3’UTR 
of p27 mediate, at least in part, the stabilisation of the mRNA upon CP treatment, and 
that (ii) the reporter is valuable for studying the factors mediating such post-
transcriptional control.  
 
Dynamic association of functionally related RBPs within the 3’UTR of p27 mRNA  
To identify proteins interacting with the 3’UTR of p27, we established tobTRIP to 
capture in vivo formed RNA-protein complexes (Figure 3(a)). After UV irradiation of 
HEK293 GFP-T-p27(3’UTR) cells to crosslink proteins to RNA in vivo, polyadenylated 
(poly(A)) RNAs were captured from a cell lysate using oligo(dT)25 beads (38,39). In a 
second step, the tagged mRNAs were enriched with tobramycin-coupled magnetic 
beads (see Materials and Methods). To control for non-specifically enriched mRNAs 
and proteins, the second purification step was performed with beads devoid of 
tobramycin. This control facilitates the monitoring of unspecific binding to beads using 
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the same input sample; however, it does not exclude the possibility for enriching 
crosslinked RNA-protein complexes that may directly interact with tobramycin. In total, 
we performed three independent isolations (biological replicates) from CP-treated and 
untreated HEK293 cells with corresponding control samples (12 samples in total).  
 The recovery of tagged mRNAs was monitored by RT-qPCR, revealing 
selective enrichment of GFP mRNA. Nevertheless, we also observed some 
enrichment in respective control samples (beads devoid of tobramycin), possibly 
reflecting non-specific binding of mRNAs to beads (Supplemental Figure S5). The 
presence of RBPs in the affinity isolates was further examined by immunoblot analysis. 
ELAVL1 and hnRNPD, both known to interact with the 3’UTR of p27 mRNA (40-42), 
were both detected in tobramycin affinity isolates but not in control samples (Figure 
3(b)). Conversely, CUGBP1, an RBP reported to bind to the 5’UTR of p27 (43) was 
identified in poly(A) RNA isolates (1st step) but was not detected in tobramycin eluates. 
-actin was not detectable in either isolate.  
 To identify mRNA bound proteins, we subjected all samples to LC-MS/MS and 
processed and analysed the data with MaxQuant LFQ mode (44). 355 proteins were 
detected with a false-discovery rate (FDR) of less than 1%. After removing reverse 
peptides and contaminants 102 proteins were identified by at least two different 
peptides in at least two out of six samples. For further analysis, we considered only 
the 54 proteins that were at least 2.5-fold enriched above the negative control samples 
(Figure 3(c)); a list of the 54 selected proteins and the complete MaxQuant analysis 
with LFQ and less-stringent iBAC analysis mode for comparison is given in the 
Supplemental Dataset S1).  
Gene Ontology (GO) enrichment analysis revealed a significant enrichment of 
RBPs among the 54 proteins (36 proteins annotated to GO-term ‘RNA binding’, P < 
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10-24), primarily acting either in ‘RNA processing’ (P < 10-8) and/or translation (P < 10-
15) (Figure 3(d); an extended subset of significantly enriched GO terms is provided in 
Supplemental Table S1). Manual inspection also revealed several proteins that have 
functional links to DNA damage response and apoptosis (e.g., CTNNB1, DSG1, DSP, 
HMGB1, HMGB2, DSC1, JUP, LTF, S100A8, PDAP1, CASP14, SAFB2); and six 
proteins (KHSRP, hnRNPA1, PABC1, PRDX2, NPM1 and GAPDH) have been directly 
linked to the CP response in human as recorded in the Comparative Toxicogenomics 
Database (CTD; (45)), which is more than expected by chance (P = 0.001, 
hypergeometric distribution; total 702 human proteins linked to CP in CTD, 
representing 2.2% of all 30,585 human protein genes in CTD). Thus, besides the 
expected overrepresentation of RBPs, the identified proteins instil functional 
annotations that relate to the chosen cellular stress conditions. 
Nevertheless, CP treatment induced only modest changes of the associations 
of mRNA-bound proteins (Figure 3(c)). Two RBPs showed more than a two-fold 
increase in associations with the reporter mRNA in CP treated cells, including RPL38, 
a ribosomal protein reported to particularly regulate the translation of HOX genes (46), 
while MRPL14 codes for a mitochondrial ribosomal protein that, we speculate, may 
relocate from mitochondria in response to CP induced mitochondrial membrane 
permeabilization (15). Conversely, 14 proteins (25% of the 54 selected proteins) were 
at least two-fold less associated with p27(3’UTR) reporter mRNAs in CP-treated cells. 
This includes 11 known RBPs (KHSRP, ELAVL2, FUBP1, UPF3B, hnRNPs A0, A1, 
A2B1, and A3; and the nucleolar proteins nucleolin and NOLC1) as well as the DNA-
binding proteins SUB1, a transcriptional co-activator, and H1FX, a histone protein 
identified as poly(A) RNA-binding protein in previous RNA-protein interactome studies 
(47). Of note, other RBPs such as ELAVL1 (log2 fold-change = -0.60) and hnRNPD 
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(log2 fold change = -0.39) showed also slightly reduced mRNA associations, broadly 
recapitulating the changes observed in the immunoblot analysis (Figure 3(b)). 
Interestingly, protein-protein interaction (PPI) network analysis with STRING 
revealed more interactions among interacting proteins than would be expected by 
chance (total 53 nodes/proteins, 111 edges, P < 10-16), supporting the notion that the 
captured proteins are biologically connected. Thereby, PPI analysis revealed a highly 
connected subnetwork of RBPs that preferentially showed reduced binding to the 
reporter mRNA upon CP treatment (Figure 3(e)). The subnetwork contains RBPs that 
function in the regulation of mRNA stability and translation, such as ELAVL1, 
hnRNPD/AUF1, hnRNPA0, and KHSRP (P < 10-4), which are known to bind to AU-
rich elements (AREs) in 3’UTRs of mRNAs (48). Since the 3’UTR of p27 mRNA 
contains several AREs including six ‘AUUUA’ core motifs (49,50), it seems possible 
that remodelling of these ARE RBPs upon CP treatment could affect p27 mRNA 
stability or translation. Overall, the significant physical and functional associations 
among interacting proteins indicates a post-transcriptional regulatory network 
involving ARE-binding and other RBPs that likely control the fate of p27 mRNA in a 
combinatorial fashion. 
 
Knock-down of candidate RBPs affects upregulation of p27 mRNA levels upon 
CP treatment in HEK293 cells 
To validate our findings, we further focused on five RBPs that were previously 
identified as a poly(A) RNA interacting proteins (38) and are implicated in cell-cycle 
control and/or the DNA damage response. The five include ELAVL1 and hnRNPD, 
both known to interact with AREs in the 3’UTR of p27 mRNAs (40-42); KHSRP, an 
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ARE-BP that regulates the stability and/or translation of mRNAs coding for proteins 
with roles in cell proliferation, differentiation and cancer (51); SNW domain containing 
protein 1 (SNW1), which was shown to regulate the transition from G1 to S phase by 
controlling cyclin D1 mRNA stability (52); and platelet-derived growth factor A 
(PDGFA) associated protein 1 (PDAP1), a mitogen-associated phosphoprotein 
involved in the DNA damage response and shown to be induced in HeLa cells exposed 
to 5-fluorouracil and CP (53).  
We first determined whether mRNA and protein levels for these RBPs changed 
in CP-treated HEK293 cells, which could explain the altered associations with reporter 
p27(3’UTR) mRNA in CP treated cells. While ELAVL1, SNW1, PDAP1 protein as well 
as ELAVL1 and SNW1 mRNA levels were slightly increased in CP treated cells, no 
significant changes were observed for KHSRP and hnRNPD (Supplemental Figure 
S6). Thus, the observed slightly diminished interaction for RBPs ELAVL1, hnRNPD, 
KHSRP, and SNW1 with p27(3’UTR) reporter mRNAs upon CP treatment does not 
coincidence with - and unlikely dependent on - changes in their abundance. However, 
the observed slight increased association of PDAP1 (~1.2-fold) with the p27(3’UTR) 
reporter mRNA in CP-treated cells coincidences with the substantially increased 
abundance of PDAP1 protein in CP-treated HEK293 cells, which is reminiscent to 
previous observations made HeLa cells exposed to CP (53). 
To further investigate the role of the RBPs in regulating p27 mRNA levels in the 
presence of CP, we knocked-down each of the five selected RBPs with siRNAs and 
measured changes of p27 mRNA and protein levels upon CP treatment of cells (Figure 
4). The previously seen induction of p27 mRNA levels upon CP treatment was 
recapitulated with scrambled (Scr) control siRNA treated HEK293 cells, indicating that 
siRNA transfections do not greatly affect the outcome. We observed an induction of 
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p27 mRNA levels upon CP treatment in hnRNPD and SNW1 knock-down cells, while 
the knock-down of PDAP1 and ELAVL1 attenuated the induction of p27 mRNA. Of 
note, similar results were obtained for ELAVL1 knock-downs upon normalisation of 
RT-qPCR data to tubulin (TUBB, 1.23-fold) or GAPDH mRNAs (0.85 fold) as 
compared to -actin mRNA which was reported to interact with ELAVL1 (54). Most 
striking, knock-down of KHSRP led to a significant decrease of p27 mRNA levels in 
CP-treated cells. These results suggest that KHSRP, and possibly ELVAL1 and 
PDAP1, are implicated in the CP-mediated induction of p27 mRNA. However, since 
the efficiency of RPB knock-downs varied between experiments and RBPs, the 
absence of measurable effects on p27 levels should be interpreted with some caution, 
especially for SNW1 and PDAP1 (representative Western blots and knock-down of 
RBPs are shown in the Supplemental Figure S7). We also monitored p27 protein 
levels, which we previously observed to slightly decrease upon CP treatment of 
HEK293 cells (Figure 1(d)). siRNA controls as well as knock-down of KHSRP, 
hnRNPD and ELAVL1 led to similar reductions of p27 protein levels upon CP 
treatment, whereas it was less pronounced in PDAP1 and SNW1 knock-downs (Figure 
4; Supplemental Figure S7). Therefore, as previously observed, the changes in p27 
mRNA levels upon CP treatment are not necessarily correlated with the changes of 
protein levels, which could either relate to additional regulatory events, such as protein 
degradation or modification, or functions of the mRNA apart from being a template for 
translation.  
 
KHSRP modulates CP-induced alterations of p27 mRNA levels and renders 
MCF7 cells sensitive to CP treatment 
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 Since knock-down of KHSRP led to significantly reduced endogenous p27 
mRNA levels upon CP treatment, we further focused our studies on this RBP that 
contains three hnRNPK-homology (KH) RNA-binding domains interacting with AREs 
in the 3’UTR of mRNA targets, thereby regulating mRNA stability and translation (51). 
To confirm interaction of KHSRP with the p27 3’UTR, we first performed RNA pull-
down experiments using synthetic biotinylated RNAs added to extract derived from 
cells expressing GFP-tagged KHSRP (Figure 5(a)). GFP-KHSRP selectively 
interacted with the 3’UTR of p27 and a RNA fragment derived from the LDLR 3’UTRs, 
a previously validated target bearing three AREs (55). Similar interactions were 
detected with ELAVL1. In either case no interaction with an unrelated control RNA 
(RASM) was observed. Of note, we also tested a predicted KHSRP binding site in the 
3’UTR of p27 (CCUCCC; identified with ScanForMotifs (49)), but we were unable to 
determine any interaction with this motif in our assay (data not shown). 
We next monitored GFP-T-p27(3’UTR) and GFP-T levels in KHSRP siRNA 
knocked-down cells to evaluate whether changes in p27 mRNA abundance by KHSRP 
following CP treatment were mediated via the 3’UTR (Figure 5(b)). No induction was 
seen in GFP-T control cells transfected with siRNA controls or siRNA against KHSRP 
upon treatment with CP. In contrast, an induction of GFP-T-p27(3’UTR) following CP 
treatment was recapitulated in siRNA control transfections, but it was significantly 
alleviated upon siRNA mediated knock-down of KHSRP. These data suggest that 
KHSRP is critically involved in the post-transcriptional regulation of p27 mRNA levels 
upon CP treatment through interaction with 3’UTR sequences.  
Finally, we wondered whether KHSRP may also influence p27 mRNA levels in 
response to CP treatment in MCF7 cells. Knock-down of KHSRP in MCF7 cells 
resulted in slightly, but significantly, reduced mRNA levels of p27 upon CP treatment, 
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which is in line with our previous observations made in HEK293 cells (Figure 5(c)). 
Interestingly, while cell-proliferation was generally not affected by siRNA mediated 
knock-down of KHSRP, we observed that it significantly attenuated cell proliferation of 
MCF7 cells after 24 h of CP treatment as compared to control siRNA transfected cells 
(Figure 5(d)). These results suggest that KHSRP is part of a regulatory network that 
controls p27 mRNA levels, and it is potentially involved in mediating CP response and 
the inferred sensitivity of cancer cells to the drug. Nonetheless, whether p27 mRNA 
regulation is directly linked to CP response possibly involving KHSRP and other RPBs 
will need to further investigation. 
 
Discussion 
Drug resistance in cancer treatments is a worldwide problem. While diverse factors 
contribute to CP resistance (14), the implications of post-transcriptional events in drug 
sensitivity are just starting to be uncovered (56,57). In this study, we observed different 
fates of p27 mRNA upon 15 h CP treatment of HEK293 compared to MCF7 breast 
cancer cells. Focusing on CP sensitive HEK293 cells, we found that p27 mRNA was 
stabilised upon CP treatment and that the 3’UTR contributes to mRNA stabilisation. 
To monitor interacting RBPs we developed tobTRIP, a novel biochemical approach 
for capturing in vivo formed RNPs on affinity-tagged 3’UTRs. This allowed us to 
identify 54 proteins that reproducibly interacted with the tagged p27(3’UTR) mRNAs. 
About 25% of these RBPs exhibited more than a two-fold change in their level of p27 
mRNA associations upon CP treatment, including KHSRP and other ARE-binding 
RBPs that likely form a post-transcriptional regulatory network. Knock-down of 
selected RBPs impeded CP induction of p27 mRNA levels in HEK293 cells, further 
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suggesting a regulatory function. Moreover, likely obstruction of the post-
transcriptional regulatory network in MCF7 breast cancer cells by knock-down of 
KHSRP significantly reduced cell proliferation upon CP treatment, emphasising the 
role of RBPs in cancer biology and drug response. 
One apparently paradoxical observation concerned the stabilisation of p27 
mRNAs upon CP treatment of HEK293 cells, while translation was generally reduced. 
This seems counterintuitive as one may expect that stabilisation of mRNAs would go 
along with increased translation or the storage of untranslated mRNAs (i.e., in stress 
granules). However, mRNAs could also have other regulatory functions in cells, albeit 
little is known about potential ‘non-coding’ functions of mRNAs. For instance, mRNAs 
or particular regions thereof (e.g., UTRs) can act as scaffold for protein complex 
assembly (58), anneal with other RNAs analogous to endogenous competing RNAs 
(ceRNA) that sequester miRNAs and thereby diminish their interaction with other 
mRNAs (59); or they could be involved in transcriptional control and epigenetic 
functions (36). Further investigations will be required to test these possibilities.  
At this point, our studies were particularly focused to develop tobTRIP, an 
approach aimed to reveal interactions of proteins with 3’UTRs of specific mRNA in 
vivo and taking the post-transcriptional control p27 mRNA in CP treated cells as a 
model system for investigation. In brief, tobTRIP is based on a cell-integrated reporter 
mRNA comprised of the coding sequences for eGFP, a tobramycin RNA aptamer 
sequence for affinity purification (HAMMER2 cassette) followed by the 3’UTR 
sequence under study. Since all components of the reporter system can be exchanged 
by cloning via restrictions sites, our primary set-up can be modified and expanded to 
other UTRs or RNA aptamers, allowing streamlined applications for parallel testing of 
many conditions. For instance, we found that the tobramycin aptamer was superior to 
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other widely used aptamers such as the streptomycin S1 aptamer (60), as we 
experienced that recovery of S1-tagged RNAs was less efficient, which is possibly due 
to its lower affinity for streptavidin (unpublished observations). In this regard, we also 
observed that initial enrichment of poly(A) RNAs with oligo(dT) beads from extracts 
was beneficial for selection affinity-tagged RNAs in a second step, as we experienced 
that direct capture of cross-linked RNP complexes from extracts was not efficient and 
led to higher background. Finally, since the mRNA reporter expresses GFP, it can also 
be used to compare the influence of different 3’UTRs on expression and localisation 
in vivo e.g. for validation of interaction partners. 
Our analysis of the proteins bound to tagged p27(3’UTR) RNA revealed 
enrichment of an array of RBPs, some of them previously linked to p27 mRNA 
regulation. This included ELAVL1, hnRNPD as well as hnRNPA0 enforcing cell cycle 
checkpoints, allowing DNA repair and tolerance to chemotherapy (24). However, we 
note that we could not detect all previously reported RBPs that regulate p27 mRNA 
through interaction with 3’UTR sequences (e.g., PUMILIO proteins (61)). The reason 
for this lack of detection could be manifold, ranging from limited MS sensitivity, low 
expression and biological variation in binding affinities across different cell-types. 
Nevertheless, our analysis revealed a subnetwork of functionally connected RBPs that 
most likely combinatorially control the fate of p27 mRNAs. Besides sharing physical 
network relations, the 54 selected proteins also have significant functional relations, 
such as the CP response, as revealed by data extraction from the CTD. Thus, while 
RBPs often bind to mRNAs coding for functionally related proteins, forming so-called 
RNA regulons (62,63), we speculate that the reverse may apply in certain instances: 
proteins interacting with certain parts of an mRNA may establish a functional coherent 
protein assemblage with potential for predicting functional outcomes.  
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SiRNA mediated knock-down of three (KHSRP, ELVAL1 and PDAP1) of the 
five selected interacting proteins revealed significant alterations on CP-mediated 
induction of p27 mRNA levels in HEK293 cells. Thereby, most striking effects were 
observed in knock-downs of KHSRP, whose association and imposed regulation on 
3’UTR sequences of p27 was confirmed by in vitro RNA pull-down assays and reporter 
assays, respectively (Figure 5(a), (b)). Interestingly, knock-down of KHSRP rendered 
MCF7 cells more sensitive to CP treatment (Fig. 5(d)). Although it is not yet resolved 
whether this increased sensitivity is directly linked to altered p27 mRNA levels, it is in 
line with previous observations that suggest the involvement of KHSRP in DNA 
damage responses induced by related drugs, such as doxorubicin (64), bleomycin 
(65), and etoposide (66). Furthermore, alterations of KHSRP levels have been 
reported upon CP treatment in different cell-lines (67,68). Interestingly, phospho-
proteome profiling in stem cells indicated that KHSRP is phosphorylated after 4 h of 
CP treatment (19). Since CP-treatment leads to activation of the p38/MK2 signalling 
pathway (69) and p38/MK2 can phosphorylate threonine 692 in the C-terminal domain 
of KHSRP, which negatively regulates ARE binding capabilities (70), it is tempting to 
speculate that phosphorylation of KHSRP through p38/MK2 could lead to the observed 
reduced mRNA binding in CP-treated HEK293 cells. Although this hypothesis needs 
further testing, a recent comparative RNA-protein interactome study in mouse 
fibroblasts subjected to DNA stress (etoposide) has highlighted the role for activation 
of the p38/MK2 signalling pathway in the regulation of cell cycle progression (66). In 
agreement with our study, it disclosed a cluster of RBPs including KHSRP and other 
RBPs (i.e., ELAVL1, hnRNPDL, hnRNPA0, and PABPC1) identified in our study that 
showed reduced mRNA associations upon etoposide treatment (66).  
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In conclusion, our biochemical approach for characterisation of RBPs 
interacting with 3’UTRs highlights critical factors for the regulation of p27 mRNAs upon 
CP treatment. It revealed that KHSRP is likely part of a post-transcriptional regulatory 
network that involves several ARE-BPs, possibly establishing a new component for 
modulation of CP drug sensitivity in cancer cells. While the potential link between p27 
mRNA regulation and CP response needs to be further established, our conceptual 
approach could be used to investigate the impact of mutations in the often-disregarded 
regions of transcripts, such as UTRs, which should be taken into consideration in the 
future era of pharmacogenomics and personalised medicine. 
 
Materials and Methods 
Cell culture and proliferation assays  
Michigan Cancer Foundation-7 breast adenocarcinoma (MCF7) cells were purchased 
from the European Collection of Authenticated Cell Cultures (ECACC, #86012803), 
Human Embryonic Kidney 293 (HEK293) and Flp-In-293 cells were obtained from 
Invitrogen (#R750-07). Cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) with High-GlutaMax-I (Life Technologies, #31966-021) supplemented with 
100 U/ml penicillin, 100 μg/ml streptomycin (Sigma, #P4333), and 10% fetal bovine 
serum (FBS; Sigma, #F7524) in standard tissue culture dishes in a humidified 
incubator at 37°C and 5% CO2. 
Proliferation assays: HEK293 and MCF7 cells were seeded (5 × 105 cells in each well) 
in triplicate in 12-well cell-culture dishes, treated with 20 µM of cisplatin (Sigma, 
#C2210000) or untreated as control and further grown for the indicated times (from 0 
to 48 h). Cells were washed twice with 500 µl of phosphate buffered saline (PBS), 
 21 
trypsinized and re-suspended in 500 µl PBS and counted with a hemocytometer. The 
fraction of live versus dead cells was determined with Trypan Blue: 10 µl of cell 
suspension was mixed with 10 µl Trypan Blue (Life Technologies, #T10282), loaded 
on a disposable slide (Invitrogen, #C10283) and counted with a Countess™ II FL 
Automated Cell Counter. 
 
Plasmid construction 
The DNA sequences comprising the tobramycin RNA aptamer, flanking sequences 
and multicloning sites (MCS), which we refer to as HAMMER2, was synthesised by 
Eurofins (MWG, Operon) and provided in pEX-A2 vectors. A fragment containing 
HAMMER2 was subcloned via flanking BamH I and Xho I restriction sites into pcDNA-
5/FRT/TO-based expression vectors (Invitrogen) that contain a tet-inducible CMV 
promotor, generating plasmid pTO-HAMMER2. The coding sequence of eGFP was 
amplified from pTO-HA-Strep-GW-FRT-eGFP (kindly provided by Alexander Wepf, 
ETH Zurich) with primers HindIII-Kozak-eGFP-fwd and eGFP-rev-MCS-BamHI (a list 
of oligonucleotides used in this study is provided in Supplemental Table S2). After 
verifying correct insertion by sequencing, the eGFP cassette was subcloned into the 
respective pTO derivative via Hind III and BamHI, generating plasmid pTO-GFP-T. 
The 3’UTR of CDKN1B/p27 (nts 1,070-2,403; RefSeq: NM_004064.3) was amplified 
by PCR from pGL3-CDKN1B-3’UTR (kindly provided by Dr. Martijn Kedde, NKI 
Amsterdam), with primers CDKN1B-3’UTR-fwd and CDKN1B-3’UTR-rev that contain 
Xho I and Not I restriction sites, respectively. The PCR fragment was then inserted 
into pCR-Blunt II-TOPO (Invitrogen) generating plasmid pCR-Blunt II-TOPO-
p27(3’UTR). After sequencing, the fragment bearing the CDKN1B/p27 3’UTR was 
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excised and subcloned via Xho I and Not I restriction sites to generate pTO-GFP-T-
p27(3’UTR). 
 
Generation of stable cell lines and transfections 
Tet-inducible stable clones were generated in Flp-In-293 cells (Invitrogen, #R750-07) 
by co-transfection with either 10 µg of pTO-GFP-T or pTO-GFP-T-p27(3’UTR) 
plasmids and 1 µg of plasmid pOG44 with Lipofectamine 2000 (Invitrogen, #11668-
027). Stable clones were selected in the presence of 200 µg/ml of hygromycin B 
(Invitrogen, #10697-010) and maintained in 50 µg/ml hygromycin B. GFP-T and GFP-
T-p27(3’UTR) HEK293 cells were cultured in 12-well plates and transfected with small-
interfering RNAs (siRNAs) and control siRNAs (Scr (71)) at ~60% cell confluency using 
Lipofectamin RNAiMAX reagent (Life Technologies, #13778-100). In brief, 3 µl of 
Lipofectamine RNAiMAX was diluted in 50 µl of Opti-Mem (Gibco, # 31985070) and 
combined with 10 pmol of respective siRNA supplied in 50 µl of Opti-Mem and 
incubated for 15 min at room temperature (RT). The mixture was added to cells, which 
were further grown in media supplemented with 1 µg/ml of tet (Fisher, #BP-912-100) 
and treated with 20 µM of CP for 15 h. Plasmid transfections were performed at 70% 
cell confluency with 2 µg of pEGFPC1-6XHis-FLKSRP (Addgene, #23001) and 
Lipofectamine 2000 (Invitrogen, #11668-027). 
 
Polysome gradient fractionation 
Cell lysis and polysomal fractionation were essentially performed as described (72). 
In brief, GFP-T-p27(3’UTR) cells were lysed in the dish with 300 µl of lysis buffer (10 
mM Tris-HCl, pH 7.5, 10 mM NaCl, 10 mM MgCl2, 1% Triton X-100, 1% sodium 
deoxycholate, 1 mM dithiothreitol (DTT), 40 U/mL RNasin (Promega, #N2611). 
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Cytoplasmic extracts were loaded onto a 20–50% linear sucrose gradient containing 
30 mM Tris–HCl (pH 7.5), 100 mM NaCl and 10 mM MgCl2. Gradients were 
centrifuged in a Beckman SW 41 rotor for 2 h at 37,000 r.p.m. and collected in 12 
fractions while continuously monitoring the absorbance at 254 nm. A control RNA 
(LysA) was added to each fraction prior to RNA isolation with Trizol and isopropanol 
precipitation (73). 
 
Fluorescence microscopy 
Live cell imaging: HEK293 cells with GFP-T or GFP-T-p27(3’UTR) were grown on a 
cover slip and GFP expression was induced with 1 µg/ml tet for 48 h. Cells were 
visualised under phase contrast and fluorescence microscopy was performed with the 
GFP filter on an EVOS FL Cell Imaging System (ThermoFisher Scientific). 
Immunofluorescence of fixed cells: Stress granule (SG) formation was induced with 
0.5 mM sodium (meta) arsenite (NaAsO2; Sigma, #S7400) for 15 min. Cells were 
washed gently with PBS and immediately incubated in 1 ml of fixing solution (4% 
formaldehyde in PBS) for 10 min, and further permeabilised with 1 ml of 0.1% Triton 
X-100 in PBS for 15 min at RT. Blocking was carried out with 1 ml of blocking solution 
(1% BSA in PBS) for 1 h at RT. Fixed cells were then incubated with primary Ras 
GTPase-activating protein-binding protein 1 (G3BP1; BD Biosciences, #611127) 
antibodies diluted 1:50 in PBS for 2 h at RT, and washed three times with PBS prior 
to the addition of anti-mouse secondary antibodies (1:200; Jackson ImmunoResearch, 
#715-025-150) for 1 h at RT in the dark. Finally, cells were washed three times with 
PBS and mounted on the slide with ProLong Gold antifade with 4′,6-diamidino-2-
phenylindole (DAPI; Life Technologies, #P36935). Confocal images were acquired on 
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a Nikon Ti-Eclipse A1M microscope fitted with a 60× oil immersion objective using 488 
nm, 561 nm and 405 nm laser excitation lines. 
 
Immunoblot analysis 
Proteins were resolved on SDS polyacrylamide (PAA) gels (12.5%) and transferred to 
nitrocellulose membranes (Bio-Rad, #1620115). Membranes were blocked in PBS 
containing 0.1% Tween-20 and 3% BSA and probed with the designated primary 
antibodies and with IRDye 800CW (Licor #926-32210, #926-32211) or IRDye 650RD 
secondary antibodies (Licor #926-68070, #926-68071). The blots were visualised with 
the Odyssey® CLx Imaging System. The following primary antibodies were used: anti-
β-actin (1:2,000; Sigma, #A1978), anti-β-Tubulin (1:2,000; Sigma, #T0198), anti–
ELAVL1 (1:500; Santa Cruz, #sc-5261), anti-KHSRP (1;1000; Cell Signalling, 
#13398), anti-SNW1 (1:1,000; Abcam, #ab67165), anti-PDAP1 (1:500; Cell Signalling, 
#4300), anti-p53 (1:1,000; Cell Signalling, #9282), anti-CDKN1B/p27 (1:500; Cell 
Signalling, #3686), anti-hnRNPD (1:1,000; Millipore, #07-260), anti-CUGBP1 (1:500; 
Santa Cruz, #sc-20003) and anti-GFP (1:2,000; Roche, #11814460001). 
 
UV crosslinking of cells and extract preparation 
Three 150 × 20 mm tissue culture dishes (Corning, #430599) of GFP-T-p27(3’UTR) 
HEK293 cells (total 6 × 107 cells) were treated with 1 µg/ml of tet for 48 h before 
harvesting. To induce the cisplatin response, 20 µM of CP was added to tet-treated 
cells after 33 h for 15 h. Thereafter, cells were washed twice with 10 ml pre-warmed 
PBS and after removal of the final rinse, 6 ml of PBS was added. Cells were exposed 
to UV light for crosslinking of protein-RNA complexes in vivo and cell-free extracts 
were prepared as described previously (10). In brief, cells were exposed on ice to UV 
 25 
light (254 nm) at 150 mJ/cm2 in a Stratalinker 1800 (Stratagene) and centrifuged at 
250 g for 5 min at 4ºC. The cell pellet was resuspended in 2 ml of lysis buffer (100 mM 
Tris-HCl, pH 7.5, 500 mM LiCl, 10 mM EDTA, 1% Triton X-100, 5 mM DTT, 20 U/ml 
DNase I (Promega, #M6101), 100 U/ml RNasin (Promega, #N2611), complete EDTA-
free protease-inhibitor cocktail (Roche, #11836170001)). Cell lysates were then 
combined (total ~6 ml) and subjected to three rounds of sonication (Soniprep150, 
MSE) and cleared by centrifugation at 15,000 g for 10 min at 4°C. Protein 
concentrations of extracts were determined using the Bradford assay with BSA as a 
reference standard. 
 
Tobramycin-based tandem RNA affinity isolations 
1st step - isolation of poly (A) RNAs: Poly(A) RNAs were isolated from extracts with 
the Dynabeads mRNA Purification Kit (Life Technologies, #61011) essentially as 
described (10). Dynabeads (1.2 ml) were equilibrated twice with 3 ml of lysis buffer 
and then combined with 5.5 ml of cell extract (~50 mg protein) and further incubated 
for 10 min at 25°C upon continuous shaking. The beads were collected with a magnet 
and washed with buffer A (10 mM Tris-HCl, pH 7.5, 300 mM LiCl, 1 mM EDTA, 0.1% 
Triton X-100) and twice with buffer B (10 mM Tris-HCl, pH 7.5, 150 mM LiCl, 1 mM 
EDTA) and finally re-suspended in 300 µl of 10 mM Tris-HCl, pH 7.5. Poly(A) RNA 
was eluted at 80°C for 2 min. The entire procedure was repeated three times by 
reapplying the supernatant to oligo(dT)25 beads. 
2nd step - affinity isolation of GFP-T-p27(3’UTR) mRNAs: GFP-T-p27(3’UTR) RNA 
was captured using the RNA aptamer for tobramycin, essentially following the strategy 
for purification of ribonucleoprotein (RNP) complexes (74). 100 mM tobramycin 
(Sigma, #T1783) was freshly prepared in coupling buffer (0.2 M NaHCO3, pH 8.3, 0.5 
 26 
M NaCl). The NHS activated magnetic beads (Pierce, #88826) were equilibrated at 
RT, mixed thoroughly for 10 s on a vortex, and 300 µl of beads were placed in a 1.5 
ml protein LoBind tube (Sigma, #Z666505). The beads were collected using a 
magnetic stand and washed by gently mixing for 15 s in 1 ml of ice cold 1 mM 
hydrochloric acid. After collecting the beads, 1 ml of 5 mM tobramycin provided in 
coupling buffer was added and the mixture was incubated over night at 4°C with 
shaking. The beads were collected and washed twice with 1 ml of 0.1 M glycine (pH 
2.0) for 15 s and washed once with 1 ml of ultrapure water (Sigma). Then, the beads 
were incubated with 1 ml quenching buffer (3 M ethanolamine-HCl, pH 9) for 2 h at RT 
on a rotator and subsequently washed once with 1 ml of ultrapure water and twice with 
1 ml of coupling buffer. Beads were kept in 300 µl of coupling buffer supplemented 
with 0.05% sodium azide at 4°C.  
 For affinity purification of tagged RNAs, 150 µl of tobramycin-coated beads 
were blocked in 1 ml of blocking solution (20 mM Tris-HCl, pH 8.1, 300 mM KCl, 1 mM 
CaCl2, 1 mM MgCl2, 0.2 mM DTT, 0.1 mg/ml tRNA (from E. coli MRE 600, Sigma 
#000000010109541001), 0.5 mg/ml BSA, 0.01% of Nonidet-P40) overnight at 4°C 
under constant agitation and then washed twice with RNA binding buffer (20 mM Tris-
HCl, pH 8.1, 145 mM KCl, 0.1 mg/ml tRNA, 1 mM CaCl2, 1 mM MgCl2, 0.2 mM DTT). 
800 µl of the eluate obtained from the first step (~70 µg poly(A) mRNA from 6 × 107 
cells) was adjusted to 900 µl in RNA binding buffer and combined with the beads and 
incubated for 2 h at RT under constant shaking. Then the beads were collected using 
a magnetic stand and the supernatant saved for further analysis. The beads were 
further washed six times with 500 µl of buffer C (20 mM Tris-HCl, pH 8.1, 125 mM KCl, 
1 mM CaCl2, 1 mM MgCl2, 0.2 mM DTT, 0.1% NP40). RNA and bound proteins were 
eluted in 300 µl of elution buffer (20 mM Tris-HCl, pH 8.1, 145 mM KCl, 5 mM 
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tobramycin, 2 mM MgCl2, 1 mM CaCl2, 0.2 mM DTT) at 50°C for 10 min in a 
Thermoshaker at 1,000 r.p.m. 250 µl of the final eluate was concentrated using a 
speed-vac and used for mass spectrometry (MS) analysis. 50 µl were kept for Western 
blot and reverse-transcription quantitative PCR (RT-qPCR) validation.  
 
Orbitrap Mass Spectrometry 
Samples were run on a SDS-PAGE gel and each gel lane cut as a single. Each slice 
was subjected to in-gel tryptic digestion using a DigestPro automated digestion unit 
(Intavis Ltd.) to minimise manual handling. The resulting peptides were fractionated 
using an Ultimate 3000 nanoHPLC system in line with an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo Scientific). In brief, peptides in 1% (vol/vol) formic acid were 
injected into an Acclaim PepMap C18 Nano-trap column (Thermo Scientific). After 
washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides were 
resolved on a 250 mm × 75 μm Acclaim PepMap C18 reverse phase analytical column 
(Thermo Scientific) over a 150 min organic gradient, using 7 gradient segments (1-6% 
solvent B over 1 min, 6-15% B over 58 min, 15-32% B over 58 min, 32-40% B over 5 
min, 40-90% B over 1 min, held at 90% B for 6 min and then reduced to 1% B over 1 
min) with a flow rate of 300 nl/min. Solvent A was 0.1% formic acid and Solvent B was 
aqueous 80% acetonitrile in 0.1% formic acid. Peptides were ionized by nano-
electrospray ionization at 2.2 kV using a stainless-steel emitter with an internal 
diameter of 30 μm (Thermo Scientific) and a capillary temperature of 250°C.  
 All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer 
controlled by Xcalibur 2.0 software (Thermo Scientific) and operated in data-
dependent acquisition mode. FTMS1 spectra were collected at a resolution of 120,000 
over a scan range (m/z) of 350-1,550, with an automatic gain control (AGC) target of 
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400,000 and a max injection time of 100 ms. The data-dependent mode was set to 
TopSpeed and the most intense ions were selected for MS/MS. Precursors were 
filtered according to charge state (to include charge states 2-7) and with monoisotopic 
precursor selection. Previously interrogated precursors were excluded using a 
dynamic window (40s, +/-10ppm). The MS2 precursors were isolated with a 
quadrupole mass filter set to a width of 1.6 m/z. ITMS2 spectra were collected with an 
AGC target of 5000, max injection time of 50 ms and HCD collision energy of 35%. 
 
MS Data Analysis 
All raw data were analysed with MaxQuant software version 1.6.0.16 (75) using the 
UniProt human database (downloaded 2017/05/23). MS/MS searches were performed 
with the following parameters: oxidation of methionine and protein N-terminal 
acetylation as variable modifications; carbamidomethylation as fixed modification; 
Trypsin/P as the digestion enzyme allowing up to two missed cleavage sites; precursor 
ion mass tolerances of 20 p.p.m. for the first search (used for nonlinear mass re-
calibration) and 4.5 p.p.m. for the main search, and a fragment ion mass tolerance of 
20 p.p.m. For identification, a maximum false-discovery rate (FDR) threshold of 1% 
was applied separately on protein and peptide levels. “Match between the runs” was 
activated, as well as “Label-free quantification” (LFQ) (at least two ratio counts were 
necessary to get an LFQ value). Two or more unique/razor peptides were required for 
protein identification and a ratio count of two or more for label free protein 
quantification in at least one sample. This produced LFQ values for a total of 165 
protein groups. MaxQuant generated LFQ intensities were normalised such that at 
each condition/time point the LFQ intensity values added up to exactly 1,000,000, 
therefore each protein group value can be regarded as a normalized microshare 
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(performed separately for each sample for all proteins that were present in that 
sample). After normalization a pseudocount (PC) of 100 was added and values were 
subsequently log2 transformed for further analysis. The MaxQuant processed data in 
LFQ and iBAC mode is available in the Supporting Dataset S1. The mass 
spectrometry proteomics data have also been deposited to the ProteomeXchange 
Consortium via the PRIDE partner repository (76) with the dataset identifier 
PXD008498. 
 
RNA isolation and RT-qPCR 
The RNA from affinity isolates was extracted with the ZR RNA MiniPrep Kit (Zymo 
#R1064). 10 μl of RNA obtained from tobTRIP eluates or 500 ng of total RNA isolated 
from extracts (input) were combined with 2.5 μM of oligo(dT)18 and 30 μM of random 
hexamer primers and reverse-transcribed (RT-) for 2 h at 42°C with the cDNA 
Synthesis Kit according to the manufacturers’ instructions (Primer Design; #RT-
nanoScript2-150). Quantitative PCR (qPCR) was performed on Applied Biosystems 
Quant-Studio 7Flex with PrecisionPLUS MasterMix premixed with SYBRgreen 
(PrimerDesign; #PrecisionPLUS-R-SY) using specific DNA primers in according to the 
manufacturer's procedures. Essentially, the enzyme was activated for 2 min at 95ºC 
followed by 40 cycles [95ºC for 10 s, 60ºC for 1 min]. The melt-curve was included at 
the end of the run to ensure specificity of the primers. The comparative Ct method was 
used to measure the amplification of mRNAs relative to β–actin (77). 
 
RNA stability measurements 
HEK293 cells were treated for 15 h with CP, while GFP-T and GFP-T-p27(3’UTR) cells 
were induced with 1 µg/ml of tet for 33 h prior to the addition of CP for 15 h. Then, 2 
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µg/ml of ActD was added for the indicated times prior to RNA isolation. 500 ng of total 
RNA was used for RT-qPCR to measure the level of GFP, p27 and c-myc mRNAs 
relative to β–actin mRNA using respective primers for the p27 ORF, GFP, c-myc, and 
β–actin. The comparative Ct method was used to calculate the mRNA levels; and 
curves were fitted, and half-life determined with GraphPad Prism using ‘one phase 
decay equation’.  
 
Synthesis of biotinylated RNAs and RNA-pull-down 
DNA templates for biotin-RNA synthesis were prepared by PCR from either 100 ng of 
genomic DNA (LDLR, RASM) or 80 ng of pGL3-p27-3’UTR plasmid with 
oligonucleotides bearing a T7 RNA polymerase promoter sequence. In particular, the 
entire 3’UTR of p27 (1,350 nts) and a fragment (nts 85-947) of the LDRL 3’UTR 
encompassing three AU-rich elements (AREs) (55) were amplified with 
oligonucleotide primer pairs T7-p27_3UTR_Fw/ P27_3’UTR_END_Rv and 
LDLR_T7Fw/ LDRL_Rev1, respectively (Table S2). A fragment (580 nts) of the CDS 
of RASM was amplified as described previously (78). Biotinylated RNAs were 
produced with T7-RNA polymerase and the Biotin RNA Labelling Mix (Roche, 
#11685597910), as instructed by the manufacturer. Cell-free extracts were prepared 
in IP buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM MgCl2, 5% glycerol, 1 mM 
DTT, 0.1% Triton X-100, 0.1 mg/ml heparin, 0.1 mg/ml tRNA, 1 mM 
phenylmethylsulfonyl chloride (PMSF), 1 µl 20 U/µl RNase OUT (Promega, 
#10777019) and Complete™ mini EDTA-free protease inhibitor tablets (Roche, 
#11836170001) by mechanical disruption of transfected (pEGFPC1-6XHis-FLKSRP) 
HEK293 cells with glass beads in a Tissue Lyser (Qiagen; 6 × 30 s; 30 Hz, 4°C). Biotin 
RNA pull-down experiments were performed essentially as described (78). 350 µg of 
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extract was combined with 10 pmol of biotinylated RNAs and RNA-protein complexes 
captured with 25 µl of streptavidin M280 Dynabeads® (Invitrogen, #11205D) and 
resolved on a 4-15% gradient SDS-PAA gel for immunoblot analysis. 
 
Protein annotation and analysis 
The human reference proteome (UP000005640) was downloaded from Uniprot 
considering Swiss-Prot reviewed entries (20,395 annotated proteins; 20. Sept 2018). 
GO enrichment analysis was performed with the Generic Gene Ontology (GO) Term 
Finder using the human reference proteome as a background to calculate Benjamini-
Hochberg corrected P-values (79). The protein-protein interaction (PPI) network of all 
identified RBPs was retrieved from STRING (vers. 10.5; (80)) with evidence sources 
restricted to experimental evidence and manually curated databases. For visualisation 
purposes, the STRING network was imported into Cytoscape (version 3.7.1) and 
arranged in circular layout and further arranged manually. The Comparative 
Toxicogenomics Database (CTD) (45) was queried for ‘Chemical-Gene interaction’ 
adding ‘cisplatin’ as the chemical and searching for ‘ANY’ Chemical-gene interaction; 
further selecting ‘protein’ as the Gene form and restrict the analysis to ‘Homo sapiens’ 
(Taxonomic ID: 9606) (18.02.2019). Data was retrieved for 702 unique human proteins 
in Excel format. Statistical overrepresentation (hypergeometric distribution) was 
calculated based on 30,585 human proteins considered in CTD. 
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Figure Legends 
Figure 1. CP affects cell proliferation and p27 mRNA stability in HEK293 but not in 
MCF7 cells. (a) Proliferation assay of cells treated (+CP; 20 µM) or not treated (-CP) 
with CP for the indicated time periods. (b) Trypan blue cell viability assay. Cells were 
counted (n = 3) and the result reported as a percentage of dead versus live cells in a 
bar plot. (c) Relative changes of p27 and p53 mRNAs in CP-treated (20 µM of CP for 
15 h) compared to untreated (-CP) HEK293 and MCF7 cells as measured by RT-
qPCR normalised to β-actin mRNA. Error bars represent the standard error of the 
mean (SEM), n = 3. *P < 0.05. (d) Immunoblot analysis with antibodies against the 
specified proteins. (e) HEK293 cells were treated with 20 µM CP for 15 h prior to the 
addition of 2 µg/ml of ActD for 30, 60, 90, 120, and 240 min. The half-life of p27 and 
c-myc mRNAs relative to β-actin was determined by RT-qPCR considering ‘one phase 
decay equation’ implemented in GraphPad Prism. Error bars represent SEM, n = 3. 
 
Figure 2. P27(3’UTR) reporter mRNA recapitulates post-transcriptional regulation in 
CP-treated cells. (a) Schematic representation of GFP-T and GFP-T-p27(3’UTR) 
reporter constructs. GFP-T cells lack exogenous p27 3’UTR sequences. (b) Changes 
in GFP and endogenous p27 mRNAs in CP-treated (+CP) compared to untreated (-
CP) GFP-T and GFP-T-p27(3’UTR) inducible cell lines. Transcript levels were 
quantified with RT-qPCR and normalised to β-actin mRNA. Error bars represent SEM, 
n = 3. *P < 0.05, **P < 0.01. (c) mRNA decay of GFP-T-p27(3’UTR) in untreated (-CP) 
and CP-treated (20 µM CP for 15 h) cells. The half-life of GFP and c-myc mRNAs was 
determined relative to β-actin with RT-qPCR and plotted as the mean, considering 
‘one phase decay equation’ implemented in GraphPad Prism. Error bars represent 
SEM, n = 2. 
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Figure 3. TobTRIP and MS analysis identifies a network of functionally related RBPs 
bound to p27(3’UTR) reporter mRNAs. (a) Schematic representation of tobTRIP for 
isolation of tagged mRNAs together with bound proteins: In a first step, poly(A) RNA-
protein complexes are isolated using oligo(dT)25 beads. In a second step, tobramycin 
aptamer-tagged RNAs are captured with tobramycin-coupled magnetic beads. (b) 
Immunoblot analysis of the indicated proteins across different steps of tobTRIP. 1:600 
of the extract (input), and 1:60 of the 1st and 2nd step eluates were loaded. A 
quantification of band intensities across the 2nd step eluates is indicated for ELAV1 
and hnRNPD. (c) Differential binding of the 54 proteins interacting with GFP-T-
p27(3’UTR) in CP-treated (+CP) versus untreated (-CP) cells. Mean LFQ values are 
plotted against log2-transformed average fold changes obtained from normalised 
intensities. (d) GO terms significantly enriched among the 54 selected proteins. Bars 
indicate the fractions of proteins annotated with the respective GO term, either across 
proteins pulled-down with the p27(3’UTR) reporter (black bars) or across the entire 
reference proteome (Uniprot; 20,395 proteins; white bars). Absolute numbers of 
proteins are shown to the right. Adjusted P-values (Benjamini-Hochberg) for 
enrichments relative to the reference proteome are indicated. (e) PPI network of 28 
proteins with multiple and propagating interactions. Each node corresponds to one 
RBP, and the physical interaction between RBPs is shown as an edge. The thickness 
of edges is proportional to the STRING confidence score (between 0-1). Node colour 
corresponds to average log2 fold-change of RNA binding in treated (+CP) versus 
untreated (-CP) cells as indicated in the colour bar. 
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Figure 4. Knock-down of candidate RBPs affect p27 mRNA abundance upon CP 
treatment in HEK293 cells. (a) Cells were transiently transfected with siRNAs 
(siKHSRP, sihnRNPD, siPDAP1, siELAVL1, siSNW1) and Scr control oligos for 48 h 
and treated with 20 µM CP for the last 15 h. P27 mRNA levels of CP-treated (+CP) 
relative to untreated cells (-CP) was assessed by RT-qPCR and normalised to β-actin 
(left). P27 protein levels were quantified with immunoblots (right). Error bars represent 
SEM, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed student’s t-test.  
 
Figure 5. KHSRP affects p27 mRNA abundance via the 3’UTR and modulates CP 
sensitivity of MCF7 cancer cells. (a) Extracts prepared from HEK293 cells expressing 
GFP-tagged KHSRP (lane 1) was incubated with biotinylated RNAs comprising a 
fragment containing AREs of the 3’UTR of LDRL mRNAs (lane 2), the 3’UTR of p27 
mRNA (lane 3), and RASM as a negative control (lane 4). RNA was captured with 
streptavidin beads and monitored for the presence of GFP-KHSRP, ELAVL1 and actin 
by immunoblot analysis with GFP, ELAVL1, and actin antibodies, respectively. (b) 
HEK293 cells expressing GFP-T and GFP-T-p27(3’UTR) were transiently transfected 
with siKHSRP or scr (siRNA control) for 48 h and treated with 20 µM CP for the last 
15 h. The level of GFP in CP-treated (+CP) versus untreated cells (-CP) was assessed 
by RT-qPCR normalised to β-actin. (c) MCF7 cells were transiently transfected with 
siRNAs targeting KHSRP (siKHSRP) and Scr control oligos. P27 mRNA levels of CP-
treated (+CP, 24 h) relative to untreated cells (-CP) was assessed by RT-qPCR 
normalised to β-actin. An immunoblot showing knock-down of KHSRP is depicted 
below. (d) Cell proliferation of MCF7 cells was determined by Trypan Blue assay at 
the indicated time points after CP treatment. Error bars represent SEM, n = 3. *P < 
0.05, ***P < 0.001, two-tailed student’s t-test. 
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Figure S1. Polysomal profiles of HEK293 cells upon CP treatment. (a) Cytoplasmic 
extracts were prepared from untreated (-CP) and CP-treated (+CP) HEK293 cells and 
fractionated on sucrose gradients while continuous monitoring the absorbance at 254 
nm. The positions of 40S and 60S ribosomal subunits, 80S monosomes and 
polysomes are indicated. (b) Distribution of p27, RPS18 and TUBB mRNAs in the 
polysomal gradients. RNA was isolated from each fraction of the polysomal profile and 
quantified by RT-qPCR. Ct-values were normalised to the LysA control RNA that was 
added to each fraction of the polysomal gradients (see Materials and Methods). The 
mRNA level in each fraction was calculated as a percentage of the total. 
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Figure S2. CP does not induce stress granules formation. Immunofluorescence 
analysis of the SG marker G3BP1 in HEK293 cells. Cells were treated with 0.5 mM 
sodium arsenite (NaAsO2) for 15 min to induce SG formation. No redistribution of 
G3BP1 was observed in cells treated with 20 µM CP for 15 h. Nuclear DNA was 
stained with DAPI (left panel). Enlargements of boxed regions depicted in the merged 
images are shown in the right panel. Scale bar: 30 µm. 
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Figure S3. The HAMMER2 affinity tag and plasmids. (a) Centroid secondary structure of the HAMMER 
tandem affinity tag as predicted by RNAfold (81). The tobramycin aptamer (highlighted in blue) is 
flanked by sequences predicted to form a stable stem-structure (orange) to expose the RNA aptamer, 
and an oligonucleotide cassette oligonucleotide (green) that could be used for enrichment with ASOs 
(not used here). (b) Nucleotides are colour-coded according to base-pair probabilities (RNAfold). (c) 
Schematic representation of the HAMMER2 tandem affinity tag, showing the linker stem regions 
(orange), the tobramycin aptamer cassette (blue), and the oligonucleotide cassette (oligonucleotide: 
25v2; green), together with the corresponding DNA sequence in the sense direction. Restriction sites 
that can be used to exchange the oligonucleotide cassettes (ClaI and NheI, respectively) are indicated. 
(d) Plasmids containing the HAMMER2 tandem affinity tag for generation of stable cell lines. The 
plasmids contain a chimeric tet operon/CMV minimal promoter (CMV/tetO; orange), allowing the tet-
inducible expression of HAMMER2-containing transcripts in mammalian cells (arrows). Transcription is 
terminated by the bovine growth hormone (bGH) terminator. The eGFP expression cassette including 
the Kozak sequence (dark and light green, respectively), the p27(3’UTR) (dark red), and multiple cloning 
sites (MCS; yellow) to facilitated exchange of aptamer tags and 3’UTRs are indicated. The pTO reporter 
plasmids contains a Flippase recognition target (FRT) site (not shown), allowing recombinase-mediated 
single site genomic integration into a range of commercially available cell-lines. 
81. Gruber, A.R., Lorenz, R., Bernhart, S.H., Neubock, R. and Hofacker, I.L. (2008) The Vienna 
RNA websuite. Nucleic acids research, 36, W70-74. 
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Figure S4. Inducible expression of GFP reporters in stable cell lines. (a) Phase 
contrast and fluorescence microscopy analysis of GFP-T and GFP-T-p27(3’UTR) cells 
treated with 1 µg/ml of tet for 24 h to induce GFP expression (+tet). Uninduced cells (-
tet) are shown for comparison. Scale bar: 100 µm. (b) Immunoblot analysis of total 
lysate of the indicated cell lines, each treated for 48 h with 1 µg/ml tet and 20 µM CP 
added (+CP), or not added (-CP) for the last 15 h. The membrane was probed with 
antibodies directed against the indicated proteins. 
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Figure S5. Enrichment of GFP-T-p27(3’UTR) in tobramycin affinity eluates. Relative 
enrichment of GFP-T-p27(3’UTR) and GAPDH (control) mRNAs was determined by 
RT-qPCR normalised to tubulin as compared to the input. RNA isolations were 
performed from CP treated (white bar) and untreated (black bar) cells. A control (ctrl.) 
was performed with beads devoid of tobramycin (n=3, SEM).  
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Figure S6. Expression of selected RBPs upon CP treatment of cells. HEK293 cells 
were treated for 15 h with 20 µM CP. (a) Immunoblot analysis antibodies directed 
against the indicated proteins on total cell lysates. (b) Fold changes of respective 
mRNAs in CP-treated compared to untreated cells determined by RT-qPCR. Data was 
normalised to β-actin (n=3, SEM).  
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Figure S7. Changes of p27 protein levels upon knock-down of selected RBPs. 
Representative immunoblots detecting p27 protein and indicated RBPs in cell lysates 
prepared from non-transfected (NT) and siRNA transfected cells (indicated on the top), 
which were treated (+CP) or not (-CP) with 20 µM CP for the last 15 h. The levels of 
RPBs were not specifically changed in control siRNA (Scr) cells as compared to NT 
cells (data not shown). The average knock-down  (KD) efficiency (fold-change) is 
indicated to the right of the RBP. Parts of the figure referring to the expression of RBPs 
in untreated cells is also displayed in Supplemental Figure S6. 
Table S1. GO term enrichment analysis.
GO category GOID Term Corr. P -value # Proteins Total # Proteins
Process GO:0006412 translation 1.8E-15 21 624
GO:0043043 peptide biosynthetic process 4.1E-15 21 649
GO:0043604 amide biosynthetic process 1.5E-13 21 777
GO:0016071 mRNA metabolic process 2.6E-12 20 779
GO:0043603 cellular amide metabolic process 5.6E-11 21 1047
GO:0006397 mRNA processing 1.4E-09 15 494
GO:0010467 gene expression 1.5E-09 39 5338
GO:0008380 RNA splicing 2.5E-09 14 421
GO:0034641 cellular nitrogen compound metabolic process 1.4E-08 41 6373
GO:0006396 RNA processing 6.8E-08 17 904
GO:1903311 regulation of mRNA metabolic process 9.3E-08 11 273
GO:0044271 cellular nitrogen compound biosynthetic process 1.1E-07 35 4813
GO:0010608 posttranscriptional regulation of gene expression 2.5E-07 13 486
GO:0006402 mRNA catabolic process 4.1E-07 11 314
GO:0006417 regulation of translation 7.6E-07 11 333
GO:0034655 nucleobase-containing compound catabolic process 1.2E-06 13 555
GO:0006414 translational elongation 1.9E-06 8 135
GO:0070125 mitochondrial translational elongation 2.6E-06 7 88
GO:0070126 mitochondrial translational termination 2.8E-06 7 89
GO:0046700 heterocycle catabolic process 3.4E-06 13 603
GO:0044270 cellular nitrogen compound catabolic process 3.4E-06 13 604
GO:0006807 nitrogen compound metabolic process 4.0E-06 47 9999
GO:0019439 aromatic compound catabolic process 4.5E-06 13 618
GO:0010629 negative regulation of gene expression 6.2E-06 20 1749
GO:0006415 translational termination 6.9E-06 7 101
GO:1901361 organic cyclic compound catabolic process 8.4E-06 13 651
GO:0044249 cellular biosynthetic process 9.0E-06 36 5925
GO:0016070 RNA metabolic process 2.0E-05 31 4549
GO:0009058 biosynthetic process 2.0E-05 36 6092
GO:0032543 mitochondrial translation 5.2E-05 7 135
GO:1901576 organic substance biosynthetic process 6.6E-05 35 6020
GO:0008152 metabolic process 9.1E-05 48 11301
GO:0006403 RNA localization 1.3E-04 8 231
GO:0044237 cellular metabolic process 1.5E-04 46 10469
GO:0140053 mitochondrial gene expression 1.7E-04 7 160
GO:0009892 negative regulation of metabolic process 1.8E-04 23 2822
GO:0044260 cellular macromolecule metabolic process 2.5E-04 40 8107
GO:0006139 nucleobase-containing compound metabolic process 2.8E-04 33 5698
GO:0045727 positive regulation of translation 5.2E-04 6 117
GO:0071704 organic substance metabolic process 5.4E-04 46 10837
GO:0046483 heterocycle metabolic process 5.6E-04 33 5854
GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 6.0E-04 6 120
GO:0050657 nucleic acid transport 6.1E-04 7 194
GO:0050658 RNA transport 6.1E-04 7 194
GO:0051236 establishment of RNA localization 6.8E-04 7 197
GO:0006725 cellular aromatic compound metabolic process 6.8E-04 33 5900
GO:0010468 regulation of gene expression 7.9E-04 28 4405
GO:0043488 regulation of mRNA stability 8.7E-04 6 128
GO:0043487 regulation of RNA stability 1.1E-03 6 134
GO:0043624 cellular protein complex disassembly 1.1E-03 7 213
GO:0034250 positive regulation of cellular amide metabolic process 1.4E-03 6 138
GO:1903313 positive regulation of mRNA metabolic process 1.4E-03 5 76
GO:1901360 organic cyclic compound metabolic process 1.6E-03 33 6102
GO:0050832 defense response to fungus 2.2E-03 4 37
GO:0061013 regulation of mRNA catabolic process 2.2E-03 6 150
GO:0015931 nucleobase-containing compound transport 2.3E-03 7 236
GO:0048255 mRNA stabilization 4.0E-03 4 43
GO:0043933 protein-containing complex subunit organization 4.5E-03 18 2151
Function GO:0003723 RNA binding 5.6E-25 36 1630
GO:0003676 nucleic acid binding 1.1E-13 38 4022
GO:0003729 mRNA binding 1.2E-10 12 238
GO:1901363 heterocyclic compound binding 9.8E-10 40 5911
GO:0003730 mRNA 3'-UTR binding 1.5E-07 7 78
GO:0003735 structural constituent of ribosome 2.5E-05 7 162
GO:0017091 AU-rich element binding 9.4E-05 4 28
GO:0035925 mRNA 3'-UTR AU-rich region binding 6.9E-04 3 14
GO:0005488 binding 9.6E-04 52 14885
GO:0003697 single-stranded DNA binding 1.0E-03 5 107
Compartment GO:1990904 ribonucleoprotein complex 1.1E-22 28 840
GO:0015934 large ribosomal subunit 1.1E-10 10 121
GO:0005840 ribosome 1.1E-10 12 230
GO:0043232 intracellular non-membrane-bounded organelle 2.6E-10 35 4157
GO:0044391 ribosomal subunit 3.8E-10 11 191
GO:0031974 membrane-enclosed lumen 7.9E-10 38 5184
GO:0044446 intracellular organelle part 2.3E-09 48 9154
GO:0032991 protein-containing complex 7.8E-09 37 5248
GO:0044422 organelle part 9.2E-09 48 9450
GO:0000315 organellar large ribosomal subunit 1.3E-06 6 57
GO:0005762 mitochondrial large ribosomal subunit 1.3E-06 6 57
GO:0043227 membrane-bounded organelle 1.6E-06 51 12306
GO:0070062 extracellular exosome 4.3E-06 21 2091
GO:1903561 extracellular vesicle 5.1E-06 21 2112
GO:0043230 extracellular organelle 5.2E-06 21 2114
GO:0043226 organelle 8.3E-06 52 13384
GO:0000313 organellar ribosome 1.7E-05 6 87
GO:0005761 mitochondrial ribosome 1.7E-05 6 87
GO:0044428 nuclear part 4.1E-05 29 4428
GO:0030057 desmosome 8.1E-05 4 25
GO:0005615 extracellular space 1.2E-04 24 3277
Columns indicate the following (from left to right): GO category (process, function, component), GO accession number, GO term, Bonferroni 
corrected P-value, number of proteins annotated to that GO term, the total number of proteins in the Uniprot reference proteome annotatedto 
that GO term. The list was restricted to terms with FDR = 0% and edited to remove redundancy. The background gene list contained 20,395 
proteins annotated in Uniprot (see Materials and Methods). The terms displayed in Fig. 3(d) are highlighted in red. 
Table S1
Table S2. Oligonucleotide sequences.
PCR Sequence (5'>3')
ELAVL1 Fwd GTGACATCGGGAGAACGAAT 
ELAVL1 Rev GCGGTCACGTAGTTCACAAA
PDAP1 Fwd CAAAGGAGCTTTCGAGGAGAG
PDAP1 Rev GTGGCATCGTCTTTTGCTTTC
SNW1 Fwd TTACCTGCACCTACTCAGCTAT
SNW1 Rev GGTCTGCCGTGATCTCTGG
CDKN1B/p27 3’UTR Fwd GTGGAGCGGGGTATGAAGA
CDKN1B/p27 3’UTR Rev TCTCTGAAAGGGACATTACATCT
CDKN1B/p27 ORF Fwd AACGTGCGAGTGTCTAACGG
CDKN1B/p27 ORF Rev CCCTCTAGGGGTTTGTGATTCT
RPS18 Fwd CCAAGAGGGCGGGAGAAC
RPS18 Rev TATTTTCCATCCTTTACATCCTTCTG
Tubulin Fwd CTGAACCACCTTGTCTCAGC
Tubulin Rev AGCCAGGCATAAAGAAATGG
Actin Primer Design, ID HK-SY-hu-600 (ACTB)
GAPDH Primer Design, ID HK-SY-hu-600 (GAPDH)
KHSRP Fwd AATGAGTACGGATCTCGGATTGG
KHSRP Rev CCGTCATCTTGCTTGAACTGTA
HNRNPD Fwd GCGTGGGTTCTGCTTTATTACC
hnRNPD Rev TTGCTGATATTGTTCCTTCGACA
LysA Fwd CTGAAAGCACAGGTGGCATA
LysA Rev AGCTCTCTCCGGATACGACA
GFP Fwd GACCACATGAAGCAGCACG
GFP Rev GGTCTTGTAGTTGCCGTCG
C-MYC Fwd ATGAAAAGGCCCCCAAGGTA
C-MYC Rev CGTTTCCGCAACAAGTCCTCT
T7-p27_3UTR_Fw taatacgactcactatagggACAGCTCGAATTAAGAATATGTTT
P27_3’UTR_END_Rv AATGAATAGCTATGGAAGTTTTCTTTA
LDLR_T7Fw1 taatacgactcactatagggAGCATTGCCTGCCAGAGCTTTG
LDLR_Rev1 GCATTCATTGACACGGGCTTTCCC
Cloning HAMMER2 and pTO vectors
HindIII-Kozak-eGFP-fwd GATTAAGCTTGCCACCATGGTGAGCAAGGGCGAGG
eGFP-rev-MCS-BamHI GGATCCGGCGCCCCCGGGGATATCTTACTTGTACAGCTCGTCCATGC
CDKN1B-3’-UTR-fwd CTCGAGACAGCTCGAATTAAGAATATGTTTCC
CDKN1B-3’-UTR-rev GCGGCCGCGAAGTTTTCTTTATTGATTACTTAATGTG
siRNA oligo sequences
siKHSRP Ambion ID 121458
siPDAP1 Ambion ID 136628
siSNW1 Ambion ID 108321
siELAVL1 Ambion ID 145882
siHNRNPD Ambion ID 145410
siSCR AAAGGACGGAGGACAUUAU[dT] [dT]; (27)
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Supplemental Materials 
Uncropped immunoblots. (a) Fig. 1d, (b) Fig. 3b, (c) Fig. 5a, (d) Fig. 5c. 
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